The RUNX1-ETO fusion protein replaces the wild-type RUNX1 protein and binds to the open chromatin region upstream of the CCND2 transcription start site (TSS), resulting in the abnormal activation of CCND2, which drives the occurrence of AML [49]. This evidence concerns the gene CCND2 and acute myeloid leukemia.